RECENT MEDICAL MANAGEMENT OF GLIOBLASTOMA
RECENT MEDICAL MANAGEMENT OF GLIOBLASTOMA
复制标题
DOI：
10.1007/978-1-4614-3146-6_3
复制
发表时间：
2012-01-01
期刊：
影响因子：
--
通讯作者：
Chang, Susan M.
中科院分区：
文献类型：
--
作者：
Johnson, Derek R.;Chang, Susan M.
本章概述了多形性胶质母细胞瘤（GBM）的标准治疗和实验性化疗。我们讨论了烷化剂的作用，主要集中在替莫唑胺（TMZ），与放射治疗相结合，是新诊断GBM的标准治疗的一部分。TMZ已被证明在延长患者生存期方面具有良好的耐受性和有效性，但肿瘤复发仍然是规律。我们综述了分子靶向药物、低分子量激酶抑制剂和单克隆抗体的发展和应用，这些药物可以阻断肿瘤生长、迁移和避免凋亡的信号通路。
This chapter contains an overview of standard of care and experimental chemotherapy treatments for glioblastoma multiforme (GBM). We discuss the role of alkylating agents, focusing primarily on temozolomide (TMZ) which, in combination with radiation therapy, is part of the standard of care treatment for newly diagnosed GBM. TMZ has proven both well tolerated and effective in prolonging patient survival, but tumor recurrence remains the rule. We review the development and use of molecularly targeted agents, low molecular weight kinase inhibitors and monoclonal antibodies that interrupt the signaling pathways exploited by tumors to grow, migrate and avoid apoptosis.